Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

A gamma-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains.

Spilman P, Lessard P, Sattavat M, Bush C, Tousseyn T, Huang EJ, Giles K, Golde T, Das P, Fauq A, Prusiner SB, Dearmond SJ.

Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10595-600. doi: 10.1073/pnas.0803671105. Epub 2008 Jul 22.

2.

A brain aggregate model gives new insights into the pathobiology and treatment of prion diseases.

Bajsarowicz K, Ahn M, Ackerman L, Dearmond BN, Carlson G, DeArmond SJ.

J Neuropathol Exp Neurol. 2012 May;71(5):449-66. doi: 10.1097/NEN.0b013e3182544680.

PMID:
22507918
3.

PrPSc accumulation in neuronal plasma membranes links Notch-1 activation to dendritic degeneration in prion diseases.

Dearmond SJ, Bajsarowicz K.

Mol Neurodegener. 2010 Jan 21;5:6. doi: 10.1186/1750-1326-5-6.

4.

Notch-1 activation and dendritic atrophy in prion disease.

Ishikura N, Clever JL, Bouzamondo-Bernstein E, Samayoa E, Prusiner SB, Huang EJ, DeArmond SJ.

Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):886-91. Epub 2005 Jan 7.

5.

Continuous quinacrine treatment results in the formation of drug-resistant prions.

Ghaemmaghami S, Ahn M, Lessard P, Giles K, Legname G, DeArmond SJ, Prusiner SB.

PLoS Pathog. 2009 Nov;5(11):e1000673. doi: 10.1371/journal.ppat.1000673. Epub 2009 Nov 26.

6.

Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.

Mayer-Sonnenfeld T, Avrahami D, Friedman-Levi Y, Gabizon R.

Cell Mol Neurobiol. 2008 Nov;28(7):1005-15. doi: 10.1007/s10571-008-9274-1. Epub 2008 Mar 19.

PMID:
18350378
7.

Gene expression profile of quinacrine-cured prion-infected mouse neuronal cells.

Fasano C, Campana V, Griffiths B, Kelly G, Schiavo G, Zurzolo C.

J Neurochem. 2008 Apr;105(1):239-50. Epub 2007 Nov 25.

8.

Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.

Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, Adkins K, Leach MW, Clarke DW, Huryn D, Abou-Gharbia M, Magolda R, Bard J, Frick G, Raje S, Forlow SB, Balliet C, Burczynski ME, Reinhart PH, Wan HI, Pangalos MN, Jacobsen JS.

J Pharmacol Exp Ther. 2009 Nov;331(2):598-608. doi: 10.1124/jpet.109.152975. Epub 2009 Aug 11.

9.

Quinacrine promotes replication and conformational mutation of chronic wasting disease prions.

Bian J, Kang HE, Telling GC.

Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6028-33. doi: 10.1073/pnas.1322377111. Epub 2014 Apr 7.

10.

Prion clearance in bigenic mice.

Safar JG, DeArmond SJ, Kociuba K, Deering C, Didorenko S, Bouzamondo-Bernstein E, Prusiner SB, Tremblay P.

J Gen Virol. 2005 Oct;86(Pt 10):2913-23.

PMID:
16186247
11.

Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.

Li T, Huang Y, Jin S, Ye L, Rong N, Yang X, Ding Y, Cheng Z, Zhang J, Wan Z, Harrison DC, Hussain I, Hall A, Lee DH, Lau LF, Matsuoka Y.

J Neurochem. 2012 Apr;121(2):277-86. doi: 10.1111/j.1471-4159.2011.07560.x. Epub 2012 Mar 13.

12.

Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.

Meier P, Genoud N, Prinz M, Maissen M, Rülicke T, Zurbriggen A, Raeber AJ, Aguzzi A.

Cell. 2003 Apr 4;113(1):49-60.

13.

An improved cell-based method for determining the γ-secretase enzyme activity against both Notch and APP substrates.

McKee TD, Loureiro RM, Dumin JA, Zarayskiy V, Tate B.

J Neurosci Methods. 2013 Feb 15;213(1):14-21. doi: 10.1016/j.jneumeth.2012.11.011. Epub 2012 Dec 7.

PMID:
23219895
14.

Prion formation correlates with activation of translation-regulating protein 4E-BP and neuronal transcription factor Elk1.

Allard EK, Grujic M, Fisone G, Kristensson K.

Neurobiol Dis. 2013 Oct;58:116-22. doi: 10.1016/j.nbd.2013.05.014. Epub 2013 Jun 3.

PMID:
23742760
15.

Targeting of prion-infected lymphoid cells to the central nervous system accelerates prion infection.

Friedman-Levi Y, Hoftberger R, Budka H, Mayer-Sonnenfeld T, Abramsky O, Ovadia H, Gabizon R.

J Neuroinflammation. 2012 Mar 21;9:58. doi: 10.1186/1742-2094-9-58.

16.

Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.

Elvang AB, Volbracht C, Pedersen LØ, Jensen KG, Karlsson JJ, Larsen SA, Mørk A, Stensbøl TB, Bastlund JF.

J Neurochem. 2009 Sep;110(5):1377-87. doi: 10.1111/j.1471-4159.2009.06215.x. Epub 2009 Jun 10.

17.

Protease-sensitive synthetic prions.

Colby DW, Wain R, Baskakov IV, Legname G, Palmer CG, Nguyen HO, Lemus A, Cohen FE, DeArmond SJ, Prusiner SB.

PLoS Pathog. 2010 Jan 22;6(1):e1000736. doi: 10.1371/journal.ppat.1000736.

18.

Therapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie.

Poli G, Corda E, Lucchini B, Puricelli M, Martino PA, Dall'ara P, Villetti G, Bareggi SR, Corona C, Vallino Costassa E, Gazzuola P, Iulini B, Mazza M, Acutis P, Mantegazza P, Casalone C, Imbimbo BP.

Prion. 2012 Jan-Mar;6(1):62-72. doi: 10.4161/pri.6.1.18317.

19.

Persistent retroviral infection with MoMuLV influences neuropathological signature and phenotype of prion disease.

Krasemann S, Neumann M, Luepke JP, Grashorn J, Wurr S, Stocking C, Glatzel M.

Acta Neuropathol. 2012 Jul;124(1):111-26. doi: 10.1007/s00401-012-0944-1. Epub 2012 Jan 24.

PMID:
22271154
20.

Gamma-secretase inhibitor reduces allergic pulmonary inflammation by modulating Th1 and Th2 responses.

Kang JH, Kim BS, Uhm TG, Lee SH, Lee GR, Park CS, Chung IY.

Am J Respir Crit Care Med. 2009 May 15;179(10):875-82. doi: 10.1164/rccm.200806-893OC. Epub 2009 Feb 20.

PMID:
19234107

Supplemental Content

Support Center